‹

News & Bulletin UpdatesNews

INDIA DOMESTIC PRICES – WHAT IS GOING ON?

Lauric Acid drops Rs 5 weekly as Ahmedabad weakness extends further now. – India Domestic Prices – What Is Going On?

IndianPetroChem

This edition covers:

  • Methanol ticks up in Kandla but stays far below three-month highs today.
  • Lauric Acid drops Rs 5 weekly as Ahmedabad weakness extends further now.
  • Acrylamide nears one-year high after gaining Rs 17 monthly in Delhi.
  • Stearic Acid dips Rs 1 but remains near recent highs in Delhi market.
  • Glycerine rebounds Rs 9 after steep monthly drop in Ahmedabad today.
  • EDC climbs Rs 1 weekly as Mumbai recovery trend stays intact today.
  • VAM slips Rs 3.5 as monthly downtrend extends in Mumbai market now.
  • Ethyl Acetate dips Rs 2 but holds strong three-month gains overall today.
  • Hydrogen Peroxide rebounds Rs 4 from recent lows in Mumbai today.
  • Benzene rises Rs 2 weekly, up Rs 41 over six months in Ahmedabad.
  • Nitrobenzene rises Rs 2 after a strong fortnightly surge in Delhi.
  • Maleic Anhydride hits one-year high, climbing Rs 17 weekly in Kandla.
  • Paraformaldehyde surges Rs 17 despite a slight monthly decline in Ahmedabad.
  • C5 edges up Rs 2, holding near recent peak in Mumbai market today.
  • Caustic Soda Flakes jump Rs 9, testing recent highs in Delhi today.
  • Heavy Soda Ash slips Rs 1, hovering near lower end of range.
  • Mancozeb drops Rs 10 but holds strong monthly gains in Mumbai.
  • PP holds steady in Chennai as polymer market consolidates recent gains.
  • PBT flat this week but up Rs 93 from a year ago in Ahmedabad.
  • ABS climbs Rs 7 in Mumbai, building on a steady monthly uptrend.
  • SEBS hits fresh high, up Rs 3 this week in Delhi rubber market.
  • SBR adds Rs 5 over fortnight, matching August peak in Ahmedabad.
  • DMF surges Rs 16 weekly, extending a strong monthly rally in Delhi.

The complete bulletin is available to subscribers.

Read the complete bulletin

Request a free trial and our team will set up your access. Subscribers log in and return to this bulletin in full.

Questions about access? Contact our team
← Browse more news & analysis